Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivosidenib and FLAG Chemotherapy in Relapsed/Refractory IDH1+ AML
NCT04250051Phase 1Terminated
- Sponsor
- Northwestern University
- Start
- Dec 2020
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ivosidenib in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and Myeloproliferative Neoplasm (MPN), sponsored by Northwestern University. Primary endpoint: Maximum Tolerated Dose. Started Dec 2020; status: terminated.
02
Drugs
ivosidenib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)Myeloproliferative Neoplasm (MPN)
Beyond the preview
Go deeper on NCT04250051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04250051.